Becton, Dickinson and Company $BDX Shares Bought by Vident Advisory LLC

Key Points

• Vident Advisory LLC increased its position in Becton, Dickinson and Company by 185.8%, owning 11,082 shares valued at $2.54 million after purchasing an additional 7,204 shares in Q1.
• Becton, Dickinson reported earnings of $3.68 per share, exceeding estimates, and had a quarterly revenue of $5.51 billion, marking a 10.4% year-over-year increase.
• The company announced a quarterly dividend of $1.04 per share, with a dividend yield of 2.2% and a payout ratio of 74.82%.

Vident Advisory LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 185.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,082 shares of the medical instruments supplier's stock after acquiring an additional 7,204 shares during the quarter. Vident Advisory LLC's holdings in Becton, Dickinson and Company were worth $2,539,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC purchased a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $27,000. REAP Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $31,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent analyst reports. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Finally, Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $1.70 on Thursday, hitting $191.31. 1,279,808 shares of the stock traded hands, compared to its average volume of 2,610,377. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a market capitalization of $54.83 billion, a PE ratio of 34.41, a PEG ratio of 1.44 and a beta of 0.27. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company's fifty day moving average is $184.22 and its 200 day moving average is $193.54.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business's revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 863 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares in the company, valued at $4,450,398.90. This represents a 3.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.